Penumbra
PEN · NYSE
$324.34+$1.93 (+0.60%)TodayMarket closed ·
Prev close $322.41
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 11.0% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- $1.21
- Revenue estimate
- $400.14M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | $1.20 | $0.88 | −26.6% |
| Q1 FY26 | $1.09 | $0.82 | −24.5% |
| Q4 FY25 | $1.12 | $1.18 | +5.0% |
| Q3 FY25 | $0.9307 | $0.97 | +4.2% |
| Q2 FY25 | $0.8299 | $0.86 | +3.6% |
| Q1 FY25 | $0.6701 | $0.83 | +23.9% |
| Q4 FY24 | $0.9067 | $0.97 | +7.0% |
| Q3 FY24 | $0.6942 | $0.85 | +22.4% |
Earnings calls
- 44th Annual J.P. Morgan Healthcare Conference
- Piper Sandler 37th Annual Healthcare Conference
- PEN - Earnings call Q3 2025
- Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Wells Fargo 20th Annual Healthcare Conference 2025
- Canaccord Genuity’s 45th Annual Growth Conference
- PEN - Earnings call Q2 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.